Archived Medical News Stories

RSSArchived Drug Trial News Stories - January 2011

Date Title Comments Rating
2011-01-31 VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers 0 None
2011-01-31 Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis 0 None
2011-01-31 GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS 0 None
2011-01-31 Scientists to commence new DNA vaccine trial for use in patients with leukemia 0 None
2011-01-31 Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial 0 None
2011-01-29 Phase III study shows tapentadol ER relieves chronic pain associated with DPN 0 None
2011-01-28 Naprosyn used in Iroko's Phase I pharmacokinetic study of naproxen 0 None
2011-01-28 Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint 0 None
2011-01-28 Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents 0 1
2011-01-28 Cetero Research completes 20,000th early-phase clinical study 0 None
2011-01-28 Arena reduces workforce by 25% and provides update on lorcaserin 0 None
2011-01-28 Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting 0 None
2011-01-28 Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis 0 5
2011-01-28 Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal 0 5
2011-01-27 Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer 0 None
2011-01-27 Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis 0 None
2011-01-27 Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain 0 None
2011-01-27 Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion 0 None
2011-01-26 ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis 1 None
2011-01-26 Anadys begins dosing in ANA598 Phase IIb study for hepatitis C 0 None
2011-01-25 FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine 0 None
2011-01-25 Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia 0 None
2011-01-25 Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial 0 None
2011-01-25 Diamyd Medical reports first quarter group total net sales of MSEK 144.5 0 None
2011-01-25 PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011 0 None
2011-01-25 Eisai to seek marketing authorization for perampanel in the U.S. and EU 0 None
2011-01-25 Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint 0 None
2011-01-25 Diamyd Medical to report European Phase III trial results for type 1 diabetes 0 None
2011-01-25 Promising results from TheraTears Nutrition pilot trial in dry eye patients 1 None
2011-01-24 Unrealistic optimism appears common in early cancer trials 0 None
2011-01-24 Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation 0 None
2011-01-24 ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011 0 5
2011-01-24 Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer 0 None
2011-01-24 Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry 0 None
2011-01-24 Senesco files SNS01-T IND for treatment of multiple myeloma 0 None
2011-01-24 Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer 0 None
2011-01-24 Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis 0 4
2011-01-24 Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis 0 None
2011-01-24 R-Tech Ueno announces completion of RK-023 Phase 2a study for androgenetic alopecia 0 None
2011-01-24 SuppreMol completes successful pre-IND meeting with U.S. FDA 0 5
2011-01-23 FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer 0 None
2011-01-21 Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer 0 5
2011-01-21 Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011 0 None
2011-01-21 Sunshine and Binghamton University enter research agreement for cancer compound 0 None
2011-01-21 MedImmune announces MEDI-573 preclinical results against many solid tumors 0 None
2011-01-21 Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D 0 None
2011-01-21 Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117 0 4
2011-01-21 MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium 0 None
2011-01-21 Positive results from nimotuzumab Phase II study for gastric cancer 0 5
2011-01-21 ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer 0 None
2011-01-20 Preliminary top-line results from levomilnacipran Phase III study for MDD 0 None
2011-01-20 FDA accepts Vertex's telaprevir NDA for six-month Priority Review 0 4.8
2011-01-20 Cognition Therapeutics closes $2.5 million Series A1 financing 0 None
2011-01-20 FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication 0 None
2011-01-20 Chelsea reports top-line data from Phase III NORTHERA extension study in NOH 0 None
2011-01-20 ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma 0 None
2011-01-20 Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study 0 None
2011-01-20 FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology 0 None
2011-01-20 Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma 0 None
2011-01-20 Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients 0 None
2011-01-20 4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer 0 None
2011-01-20 Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl 0 None
2011-01-20 FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review 0 None
2011-01-20 GSK and Prosensa commence GSK2402968 Phase III study in DMD 0 4
2011-01-20 Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease 0 None
2011-01-20 Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia 0 None
2011-01-19 Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia 0 None
2011-01-19 Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development 0 None
2011-01-19 Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas 0 None
2011-01-19 New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux 0 None
2011-01-19 RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma 0 None
2011-01-19 Arrowhead increases ownership in Calando's outstanding equity to 79% 0 None
2011-01-19 Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma 0 1
2011-01-19 UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients 0 None
2011-01-18 NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer 0 None
2011-01-18 Alexza completes FDA review for AZ-004 NDA 0 None
2011-01-18 RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds 0 None
2011-01-18 Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV 0 None
2011-01-17 Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain 0 None
2011-01-14 Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial 0 4.3
2011-01-14 Merck announces changes in vorapaxar clinical studies 0 None
2011-01-13 Adjunctive lacosamide reduces seizures and improves responder rates 0 None
2011-01-13 BioCryst reports positive results from peramivir Phase 3 study in influenza 0 None
2011-01-13 BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease 0 None
2011-01-13 FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis 0 3
2011-01-13 MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma 0 None
2011-01-13 Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women 0 None
2011-01-13 TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers 0 None
2011-01-13 Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer 0 None
2011-01-12 AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials 0 None
2011-01-12 GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease 0 5
2011-01-12 Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC 0 None
2011-01-12 Scientists find way to prevent early stage pancreatic cancer in research models 0 5
2011-01-12 Epigenetic therapy holds promise for cancer management 0 None
2011-01-12 UH, Case Western University commence clinical trial for bipolar disorder 0 1
2011-01-11 Rib-X raises $20M to support development of broad spectrum antibiotics pipeline 0 None
2011-01-11 FemmePharma completes FP 1097 Phase II clinical trial in women with OAB 0 None
2011-01-11 SciClone initiates phase 2b study of SCV-O7 for oral mucositis 0 None
2011-01-11 ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis 0 None
2011-01-11 Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML 0 None
2011-01-11 Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma 0 1
2011-01-11 Study supports use of telomerase inhibitors for treatment of childhood cancers 0 5
2011-01-11 Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure 0 None
2011-01-11 TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders 0 None
2011-01-11 DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent 0 None
2011-01-11 Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV 0 None
2011-01-11 Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval 0 None
2011-01-11 NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome 0 None
2011-01-11 LibiGel may be the first FDA approved product to treat HSDD in menopausal women 0 5
2011-01-10 Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia 0 5
2011-01-10 Celator, Cephalon extend cancer research agreement 0 None
2011-01-10 Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program 0 None
2011-01-10 Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea 0 None
2011-01-10 Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation 0 None
2011-01-10 Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy 0 None
2011-01-10 Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer 0 None
2011-01-10 Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study 0 None
2011-01-10 FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer 0 None
2011-01-10 KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat 0 3
2011-01-10 Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus 0 None
2011-01-10 FDA, EMA accept boceprevir for expedited review 0 None
2011-01-10 Positive PK study results from ECLIPSE trial against cardiovascular disease 0 None
2011-01-10 Positive results form INX-189 Phase 1b trial against hepatitis C virus 0 5
2011-01-09 AFQ056 drug improves symptoms in Fragile X patients: Study 0 None
2011-01-07 MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody 0 None
2011-01-07 Synergy's plecanatide Phase II/III trial to begin in second quarter 2011 0 None
2011-01-07 Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen 0 None
2011-01-07 Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses 0 5
2011-01-07 Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction 0 None
2011-01-07 BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer 0 None
2011-01-07 Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs 0 None
2011-01-07 Plexxikon, Genentech enter PLX4032 co-promotion agreement 0 None
2011-01-07 ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly 0 None
2011-01-07 Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients 0 None
2011-01-07 Athersys completes patient enrollment in MultiStem Phase I study for leukemia 0 None
2011-01-07 Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan 0 None
2011-01-07 Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases 0 None
2011-01-07 Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol 0 None
2011-01-07 CeNeRx commences TriRima Phase II trial for treatment resistant depression 0 None
2011-01-06 Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis 0 None
2011-01-06 Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy 0 None
2011-01-06 MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer 0 None
2011-01-06 Choosing between EGFR therapeutic options in metastatic colorectal cancer 0 None
2011-01-06 Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211 0 2
2011-01-06 Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV 0 None
2011-01-06 Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer 0 None
2011-01-06 Positive topline results from ZGN-433 Phase 1b study in obesity patients 0 4.5
2011-01-06 Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation 0 None
2011-01-06 DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes 0 None
2011-01-05 Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis 0 None
2011-01-05 SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML 0 1
2011-01-05 Alnylam presents ALN-VSP Phase I trial results for liver cancer 0 None
2011-01-05 Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors 0 None
2011-01-05 Spectrum submits FUSILEV sNDA for treatment of colorectal cancer 0 None
2011-01-05 FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention 0 None
2011-01-05 Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease 0 None
2011-01-04 Anadys begins ANA598 Phase IIb study for hepatitis C 0 None
2011-01-04 FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial 0 None
2011-01-04 Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer 0 None
2011-01-03 Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism 0 None
2011-01-03 FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia 0 None
2011-01-03 Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment 0 None

Total

162 posts
2 comments
34 raters